KARL D KIEBURTZ

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint Discovering neuroprotection in Parkinson's disease, or getting to haphazard
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, NY, USA
    Mt Sinai J Med 77:700-6. 2010
  2. doi request reprint Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, New York 14620, USA
    Mov Disord 26:37-44. 2011
  3. doi request reprint Therapeutic strategies to prevent motor complications in Parkinson's disease
    Karl Kieburtz
    University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 223, Rochester, NY 14620, USA
    J Neurol 255:42-5. 2008
  4. ncbi request reprint Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy
    Karl Kieburtz
    Neurology Department, University of Rochester Medical Center, Rochester, New York 14620, USA
    Mt Sinai J Med 74:7-14. 2007
  5. ncbi request reprint Issues in neuroprotection clinical trials in Parkinson's disease
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, New York, USA
    Neurology 66:S50-7. 2006
  6. ncbi request reprint Why hasn't neuroprotection worked in Parkinson's disease?
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, NY, USA
    Nat Clin Pract Neurol 3:240-1. 2007
  7. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
  8. ncbi request reprint Levodopa and the progression of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    N Engl J Med 351:2498-508. 2004
  9. doi request reprint The relationship between CAG repeat length and clinical progression in Huntington's disease
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 23:1223-7. 2008
  10. pmc Long term understanding of study information in research participants with Parkinson's disease
    Bernard Ravina
    University of Rochester, School of Medicine and Dentistry, Department of Neurology, Rochester, NY 14610, USA
    Parkinsonism Relat Disord 16:60-3. 2010

Research Grants

Collaborators

Detail Information

Publications30

  1. doi request reprint Discovering neuroprotection in Parkinson's disease, or getting to haphazard
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, NY, USA
    Mt Sinai J Med 77:700-6. 2010
    ..Any possible insights will require confirmation in rigorous clinical trial testing. Combining the useful insights from all perspectives may be the most promising approach to discovering a neuroprotective therapy...
  2. doi request reprint Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, New York 14620, USA
    Mov Disord 26:37-44. 2011
    ..In this fixed dosage, randomized study pramipexole administered twice daily at a total daily dosage of 1.0-1.5 mg daily was of comparable efficacy and tolerability to a dosage of 0.5 mg tid over a 12-week treatment period in early PD...
  3. doi request reprint Therapeutic strategies to prevent motor complications in Parkinson's disease
    Karl Kieburtz
    University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 223, Rochester, NY 14620, USA
    J Neurol 255:42-5. 2008
    ..These data have led to evidence-based medicine evaluations indicating that the use of dopamine agonists is efficacious and clinically useful for the prevention of motor complications...
  4. ncbi request reprint Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy
    Karl Kieburtz
    Neurology Department, University of Rochester Medical Center, Rochester, New York 14620, USA
    Mt Sinai J Med 74:7-14. 2007
    ....
  5. ncbi request reprint Issues in neuroprotection clinical trials in Parkinson's disease
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, New York, USA
    Neurology 66:S50-7. 2006
    ..Improved clinical trial design along with continued new insights into PD pathogenesis will likely lead to the identification of agents which can favorably influence the course of this disease...
  6. ncbi request reprint Why hasn't neuroprotection worked in Parkinson's disease?
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, NY, USA
    Nat Clin Pract Neurol 3:240-1. 2007
  7. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
    ..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
  8. ncbi request reprint Levodopa and the progression of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    N Engl J Med 351:2498-508. 2004
    ..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease...
  9. doi request reprint The relationship between CAG repeat length and clinical progression in Huntington's disease
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 23:1223-7. 2008
    ..This finding may account for the variable results from previous studies examining CAGn and progression. Adjusting for CAGn may be important for clinical trials...
  10. pmc Long term understanding of study information in research participants with Parkinson's disease
    Bernard Ravina
    University of Rochester, School of Medicine and Dentistry, Department of Neurology, Rochester, NY 14610, USA
    Parkinsonism Relat Disord 16:60-3. 2010
    ..Little is known about research participants' understanding of consent information over the course of a clinical study and the relationship of this information with participant behavior...
  11. doi request reprint A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 24:2081-90. 2009
    ..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data...
  12. doi request reprint A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster
    Robert H Dworkin
    Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642, USA
    Pain 142:209-17. 2009
    ....
  13. pmc The relationship between uric acid levels and Huntington's disease progression
    Peggy Auinger
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, USA
    Mov Disord 25:224-8. 2010
    ..If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression...
  14. pmc Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study
    Kevin M Biglan
    University of Rochester, Rochester, New York, USA
    Mov Disord 24:1763-72. 2009
    ..Longitudinal assessment will help inform whether motor items will be useful measures in preventive clinical trials...
  15. pmc Fatigue in levodopa-naive subjects with Parkinson disease
    G Schifitto
    University of Rochester, NY, USA
    Neurology 71:481-5. 2008
    ..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial...
  16. ncbi request reprint Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    Ira Shoulson
    University of Rochester Medical Center, Rochester, NY 14620, USA
    Ann Neurol 51:604-12. 2002
    ....
  17. ncbi request reprint Needed in MS: evidence, not EVIDENCE
    Karl Kieburtz
    Department of Neurology, University of Rochester Medical Center, NY 14642, USA
    Neurology 59:1482-3. 2002
  18. ncbi request reprint Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial
    Thomas Guttuso
    Department of Neurology, University of Rochester, Rochester, New York 14642, USA
    Obstet Gynecol 101:337-45. 2003
    ..To evaluate whether treatment with the anticonvulsant gabapentin may be effective in reducing hot flash frequency and severity...
  19. ncbi request reprint Designing neuroprotection trials in Parkinson's disease
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, NY 14620, USA
    Ann Neurol 53:S100-7; discussion S107-9. 2003
    ....
  20. ncbi request reprint Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  21. ncbi request reprint TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 5:1013-20. 2006
    ..TCH346 is a potent anti-apoptotic drug that protects against loss of dopaminergic neurons in laboratory models. Our aim was to assess TCH346 as a neuroprotective drug in patients with Parkinson's disease...
  22. ncbi request reprint Malignant melanoma in early Parkinson's disease: the DATATOP trial
    Radu Constantinescu
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
    Mov Disord 22:720-2. 2007
    ..The standardized event ratio was 3.3 (95% confidence interval, 1.1-7.8), indicating that incidence of malignant melanoma was higher than expected. We found no association between levodopa therapy and the incidence of melanoma...
  23. ncbi request reprint Impact of pramipexole on the onset of levodopa-related dyskinesias
    Radu Constantinescu
    Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
    Mov Disord 22:1317-9. 2007
    ....
  24. ncbi request reprint A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone)
    Radu Constantinescu
    Department of Neurology, Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, New York, USA
    J Clin Pharmacol 47:1580-6. 2007
  25. ncbi request reprint An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection
    Jeffrey J Sevigny
    Department of Neurology and Gertrude H Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Arch Neurol 64:97-102. 2007
    ..Several markers of immune activation have been identified as potential prognostic markers for human immunodeficiency virus (HIV)-associated morbidity and mortality, but the results from studies are conflicting...
  26. doi request reprint Why have we failed to achieve neuroprotection in Parkinson's disease?
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, USA
    Ann Neurol 64:S101-10. 2008
    ..New developments in understanding the cause of the disease, in the development of animal models of PD, and in clinical trial methodology will hopefully hasten the resolution of these problems...
  27. pmc Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants
    K Marder
    Departments of Neurology and Psychiatry, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Gertrude H Sergievsky Center, Columbia University, New York, NY 10032, USA
    Neurology 73:385-92. 2009
    ..To examine caloric intake, dietary composition, and body mass index (BMI) in participants in the Prospective Huntington At Risk Observational Study (PHAROS)...
  28. doi request reprint Defining disease-modifying therapies for PD--a road map for moving forward
    C Warren Olanow
    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 25:1774-9. 2010
    ..Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease...
  29. pmc Pivotal studies of orphan drugs approved for neurological diseases
    Jun Mitsumoto
    College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Ann Neurol 66:184-90. 2009
    ..To identify design elements of clinical trials leading to US Food and Drug Administration approval of drugs for neurological diseases with and without orphan indications...

Research Grants3

  1. MIDCAREER INVESTIGATOR AWARD--PATIENT ORIENTED RESEARCH
    Karl Kieburtz; Fiscal Year: 2003
    ..abstract_text> ..
  2. Neuroprotection Studies in PD: A Coordinating Center
    Karl Kieburtz; Fiscal Year: 2007
    ..An appropriate research infrastructure combined with relevant scientific expertise is in place to conduct the proposed studies of neuroprotective agents in PD. ..